Products & Pipeline

Diamyd Medical's pipeline is based on the patent-protected GAD technology for the treatment and prevention of autoimmune diabetes. GAD is the active substance in the diabetes vaccine Diamyd®.

Two researcher initiated clinical studies with Diamyd® are in progress: A Swedish Phase II study, DiAPREV-IT, aiming to evaluate whether Diamyd® can prevent or delay type 1 diabetes in children who are at high risk of developing the disease and; a Swedish Phase II study, DIABGAD-1, where Diamyd® is tested in a unique combination with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen in newly diagnosed type 1 diabetes children and adolescents, aiming to potentiate the effect of the Diamyd® diabetes vaccine to preserve the body´s own ability to control the blood sugar level.